Fraud Investigation: Levi & Korsinsky Investigates Corcept Therapeutics Incorporated (CORT) on Behalf of Shareholders

Core Insights - Corcept Therapeutics Incorporated is under investigation for potential violations of federal securities laws following a Complete Response Letter (CRL) from the FDA regarding its new drug application for relacorilant [1][2] - The FDA's decision was based on the need for additional evidence of effectiveness despite acknowledging previous trial results [2] - Following the announcement, Corcept's stock price experienced a significant drop of $31.42, equating to a 44.76% decrease, marking a new 52-week low [2][3] Company Overview - Corcept Therapeutics focuses on developing treatments for patients with conditions related to hypercortisolism, specifically hypertension [1] - The company has faced challenges in gaining FDA approval for its drug relacorilant, which has implications for its market position and investor confidence [2] Market Reaction - The stock price decline to $38.78 per share reflects investor concerns over the FDA's decision and the potential impact on the company's future [2][3] - The drop in stock price indicates a significant loss of value for shareholders, prompting investigations into the company's compliance with securities laws [1][3]